Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL982446 | 0.89 | GABRA1 (0.47) | TSHRALDH1A1TDP1GABRA1GABRB2 | |
| SCHEMBL1834154 | 0.84 | TSHR (0.42) | TSHRALDH1A1TDP1GABRA1GABRB2 | |
| SCHEMBL982784 | 0.81 | TSHR (0.52) | TSHRALDH1A1TDP1GABRA1GABRB2 | |
| SCHEMBL1837834 | 0.79 | ALDH1A1 (0.43) | TSHRALDH1A1TDP1 | |
| SCHEMBL1953229 | 0.78 | GABRA1 (0.39) | TSHRALDH1A1TDP1GABRA1GABRB2 | |
| SCHEMBL1840175 | 0.77 | TYR (0.41) | TSHRALDH1A1TDP1 | |
| SCHEMBL9577896 | 0.77 | ALDH1A1 (0.45) | TSHRALDH1A1TDP1GABRA1GABRB2 | |
| SCHEMBL584830 | 0.76 | ALDH1A1 (0.71) | TSHRALDH1A1TDP1GABRA1GABRB2 | |
| SCHEMBL29613273 | 0.76 | ALDH1A1 (0.71) | TSHRALDH1A1TDP1GABRA1GABRB2 | |
| SCHEMBL986500 | 0.75 | TSHR (0.46) | TSHRALDH1A1TDP1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322504-B9 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED CARBAMIC ACID ESTER AND PROCESS FOR THE PREPARATION OF ISOCYANATE USING THE N-SUBSTITUTED CARBAMIC ACID ESTER | ASAHI CHEMICAL IND (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-2322504-B1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED CARBAMIC ACID ESTER AND PROCESS FOR THE PREPARATION OF ISOCYANATE USING THE N-SUBSTITUTED CARBAMIC ACID ESTER | ASAHI CHEMICAL IND (JP) | 2016-09-28 | — | — | EP | disclosed |
| US-9249090-B2 | N-substituted carbamic acid ester production method and isocyanate production method using the N-substituted carbamic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20150038742-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-02-05 | — | — | US | disclosed |
| US-8884047-B2 | N-substituted carbamic acid ester production method and isocyanate production method using the N-substituted carbamic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-11-11 | — | — | US | disclosed |
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-06-30 | — | — | US | disclosed |
| EP-2322504-A1 | PROCESS FOR THE PREPARATION OF N-SUBSTITUTED CARBAMIC ACID ESTER AND PROCESS FOR THE PREPARATION OF ISOCYANATE USING THE N-SUBSTITUTED CARBAMIC ACID ESTER | Asahi Kasei Chemicals Corporation (JP) | 2011-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160476-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ALKBH3, CPS1, APEH | TSHR 2998/4885ALDH1A1 574/4885TDP1 3561/4885 |
| US-20150038742-A1 | N-Substituted Carbamic Acid Ester Production Method and Isocyanate Production Method Using the N-Substituted Carbamic Acid Ester | ALKBH3, CPS1, APEH | TSHR 2998/4885ALDH1A1 574/4885TDP1 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.